EMEA-002068-PIP01-16-M04

Invented name	Flucelvax Tetra
Active substance	Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) [QIVc]
Therapeutic area	Vaccines
Decision number	P/0492/2021
PIP number	EMEA-002068-PIP01-16-M04
Pharmaceutical form(s)	Suspension for injection
Condition(s) / indication(s)	Prevention of influenza
Route(s) of administration	Intramuscular use
Contact for public enquiries	Seqirus Netherlands B.V. E-mail: seqirus.clinicaltrials@seqirus.com Tel: +1 9088587365
Decision type	PM: decision on the application for modification of an agreed PIP

Add your rating

★ ★ ★ ★ ★